NCT01209078View on ClinicalTrials.gov

GSK1322322 Versus Linezolid in the Treatment of Acute Bacterial Skin and Skin Structure Infection

PHASE2CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

August 17, 2010

Primary Completion Date

January 18, 2011

Study Completion Date

January 18, 2011

Conditions
Skin Infections, Bacterial
Interventions
DRUG

GSK1322322

GSK1322322 1500mg BID

DRUG

Linezolid

Linezolid 600mg

DRUG

GSK1322322 placebo

Placebo

DRUG

Linezolid placebo

placebo

Trial Locations (7)

19611

GSK Investigational Site, West Reading

36207

GSK Investigational Site, Anniston

90813

GSK Investigational Site, Long Beach

91911

GSK Investigational Site, Chula Vista

91942

GSK Investigational Site, La Mesa

92056

GSK Investigational Site, Oceanside

96813

GSK Investigational Site, Honolulu

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01209078 - GSK1322322 Versus Linezolid in the Treatment of Acute Bacterial Skin and Skin Structure Infection | Biotech Hunter | Biotech Hunter